Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX · Real-Time Price · USD
0.882
-0.068 (-7.15%)
At close: Apr 28, 2026, 4:00 PM EDT
0.898
+0.016 (1.78%)
After-hours: Apr 28, 2026, 6:54 PM EDT
Lexaria Bioscience Employees
Lexaria Bioscience had 7 employees as of August 31, 2025. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$52,571
Profits / Employee
-$1,361,417
Market Cap
21.87M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Vistagen Therapeutics | 59 |
| Quince Therapeutics | 38 |
| Curis | 24 |
| Jasper Therapeutics | 22 |
| OSR Holdings | 22 |
| NewcelX | 15 |
| Serina Therapeutics | 13 |
| VYNE Therapeutics | 10 |
LEXX News
- 5 days ago - Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs - TheNewswire
- 7 days ago - Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales - Accesswire
- 13 days ago - Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property - TheNewswire
- 21 days ago - Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval - TheNewswire
- 27 days ago - Lexaria to Begin New Human Clinical Study in GLP-1 - TheNewswire
- 4 weeks ago - Lexaria's Robust Patent Portfolio Continues to Grow - Accesswire
- 5 weeks ago - Lexaria's Oral GLP-1 Drug Strategy Validated by Industry - TheNewswire
- 7 weeks ago - Lexaria Announces New R&D Plans for 2026 - Accesswire